Aurora Cannabis Inc (NASDAQ: ACB) is in focus today after buying the remaining 90% stake in MedReleaf Australia for about AU$50 million ($32.45 million).Details of Aurora-MedReleaf transactionCopy link to sectionThe licensed cannabis producer paid $9.45 million in cash and the remaining in stock. Aurora caught interest in buying MedReleaf because it’s currently the second largest player in medical cannabis in Australia. Miguel Martin – chief executive of the Edmonton-headquartered firm said in a press relea ...

Core Insights - Aurora Cannabis Inc. reaffirms its commitment to achieving positive free cash flow in the current calendar year and reports its fifth consecutive quarter of positive adjusted EBITDA [1][3] - The company has become the largest global medical cannabis company in nationally legal markets following the acquisition of MedReleaf Australia, which is expected to enhance its revenue and EBITDA [2][3] - Aurora's international medical net revenue grew by 41% year-over-year, indicating strong demand and market expansion [2][5] Financial Performance - Total net revenue for Q3 2024 was $64.4 million, a 5% increase from $61.1 million in the prior year period, driven by growth in the global medical cannabis business [4][12] - Medical cannabis net revenue reached $45.1 million, a 16% increase from the prior year quarter, contributing 70% of total consolidated net revenue [5][12] - Adjusted gross margin before fair value adjustments improved to 50% in Q3 2024, up from 46% in the prior year quarter [4][12] Operational Highlights - The company reported a cash position of over $200 million as of the quarter close, with remaining convertible debt of $7.3 million expected to be fully repaid in February 2024 [1][11] - Adjusted SG&A expenses were $27.5 million in Q3 2024, reflecting effective cost control measures [8][12] - The average net selling price of dried cannabis was $4.77, a slight increase from $4.71 in the prior year [13][12] Future Expectations - For fiscal Q4 2024, the company anticipates steady revenue from Canadian medical and consumer segments, with modest growth expected in Europe and Australia [10][12] - Continued positive adjusted EBITDA is expected in Q4 2024, supported by revenue increases and ongoing cost control [10][12] - The company aims to achieve $40 million in annualized cost efficiencies by the end of the fiscal year [3][12]

Core Viewpoint - Aurora Cannabis Inc. has acquired the remaining 90% equity interest in MedReleaf Australia for an enterprise value of AUD$50 million, positioning itself as the largest global medical cannabis company in legally operating markets [2][5][9]. Company Overview - Aurora Cannabis is a leading global medical cannabis company based in Canada, with a focus on both medical and consumer markets [10]. - The company operates under various brands, including MedReleaf, CanniMed, and Aurora, and is committed to high-quality cannabis products [10]. Transaction Details - The acquisition of MedReleaf Australia involved a cash payment of AUD$9.45 million and the issuance of approximately 69.5 million common shares of Aurora [2][9]. - MedReleaf Australia is a significant player in the Australian medical cannabis market, which is valued at approximately AUD$400 million [2][3]. Market Position and Growth - The Australian medical cannabis market is rapidly growing, characterized by a clinician-led distribution model that aligns with Aurora's operational strategies in other markets like Germany [3][7]. - MedReleaf Australia generated trailing 12-month net revenue of approximately AUD$40 million as of December 31, 2023, and was adjusted EBITDA positive [8]. Strategic Rationale - The acquisition strengthens Aurora's presence in Australia, enhancing its global cannabis leadership and aligning with its strategy to invest in sustainable growth markets [5][7]. - The transaction is expected to improve revenue contributions and gross margins, further aligning Aurora's Australian operations with its profitable international markets [7][8]. Future Outlook - The transaction is anticipated to be immediately accretive to Adjusted EBITDA and will support Aurora's goal of achieving positive free cash flow in calendar 2024 [2][5][8].

The Leading Cannabis ETFs to Consider in 2024Cannabis ETFs are garnering attention in 2024 as the industry shows promising growth. Key players like MJ, MSOS, and CNBS dominate this sector. These ETFs offer diversified exposure to cannabis-related stocks. This includes companies involved in cultivation, production, and retail. The U.S. cannabis industry has seen remarkable growth. Statistics reveal a projected market size of over $30 billion by 2025. This growth is fueled by expanding legalization and increa ...

The last decade saw a trend for destigmatization of the use of psychoactive substances accompanied by a wave of legislation either legalizing or decriminalizing mostly marijuana-based products – both for medical and recreational use.These developments brought the creation of numerous firms focusing on cannabis products, and many of them have become popular publicly traded companies and exciting investment opportunities.Now, a new Food and Drug Administration (FDA) report stating that Marijuana is eligible f ...

Cannabis stocks are notching their second day of gains after the Drug Enforcement Administration confirmed it’s reviewing an August recommendation from the U.S. Department of Health and Human Services (HHS) to change the classification of marijuana to Schedule III from Schedule I under the Controlled Substances Act. In a letter to Rep. Earl Blumenauer, Democrat of Oregon, the DEA said it has “final authority” to make any rescheduling decisions. The Schedule III classification would potentially eliminate th ...

Aurora Cannabis (ACB -3.01%) stock capped off yet another bad year in 2023, with its shares falling by more than 45%. But this isn't new for investors; Aurora has consistently been a bad buy. This marks the sixth consecutive year that Aurora's stock has fallen by at least 30%. It's a painful but important reminder to investors that just because a stock has declined significantly doesn't mean it's due for a recovery -- or can't fall still more. For Aurora to turn things around for investors, it needs to be a ...

Aurora Mobile Limited (NASDAQ:JG) Q3 2023 Results Conference Call November 16, 2023 7:30 AM ET Company Participants Rene Vanguestaine - Chairman & CEO Shan-Nen Bong - Chief Financial Officer Guangyan Chen - General Manager Conference Call Participants Calvin Wong - Spica Capital Operator Ladies and gentlemen, thank you for standing by, and welcome to the Aurora Mobile Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and- ...

I N V E S T O R P R E S E N T A T I O N Disclaimer ...

Financial Data and Key Metrics Changes - Total net revenue increased by 30% in Q2, reaching $63.4 million compared to $48 million in the same period last year [18][19] - Adjusted EBITDA grew to $3.4 million, marking a $9.6 million improvement year-over-year and the highest result on record [7][18] - Adjusted gross margin held steady at 51%, with medical cannabis adjusted gross margin at 63% [19][20] Business Line Data and Key Metrics Changes - Medical cannabis segment revenue rose by 42% to $43.8 million, with international medical revenue up 126% to $18.4 million [18][19] - Canadian medical cannabis revenue increased by 11% to $25.4 million [19] - Consumer cannabis net revenue decreased by 8% to $12 million, attributed to the exit from the U.S. CBD business and timing of new product launches [20] Market Data and Key Metrics Changes - In Canada, Aurora maintained its leadership position in the medical cannabis market, benefiting from a broad product assortment and innovation [8][9] - In Germany, Aurora is one of only three companies with a production facility, and the market is expected to expand significantly with potential de-scheduling of cannabis [11][48] - In Poland, Aurora held the number one market position by volume in Q2, leveraging regulatory expertise [11] - Australia is anticipated to become the largest medical cannabis market outside the U.S., with significant sales volumes driven by clinician education [12][43] Company Strategy and Development Direction - The company is focused on innovation and plans to launch a steady stream of new products in Canada, which will also inform international market launches [9] - Aurora aims to achieve positive free cash flow in calendar 2024, supported by a strong balance sheet and reduced debt [8][16] - The company is diversifying its business model by leveraging Bevo's plant propagation business, which is expected to double revenue and EBITDA over the next two to three years [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing disruption in the Canadian marketplace and the potential for growth in medical cannabis [8][9] - The company is optimistic about the legislative changes in Germany that could expand the medical market significantly [48] - Management emphasized the importance of maintaining profitability and focusing on high-margin medical cannabis products [56] Other Important Information - The company has reduced its debt by approximately $531 million over the last three years, with plans to pay off the remaining convertible senior notes by the end of fiscal Q4 [17][26] - The company is committed to achieving $40 million in annualized savings by the end of the fiscal year [16][22] Q&A Session Summary Question: Update on Bevo's revenue doubling target - Management refrained from providing specific guidance but expressed confidence in Bevo's potential for expansion based on early market feedback [28][30] Question: Strategic fit of Tasty's launch - Management explained that Tasty's is designed to leverage existing resources without detracting from higher-margin medical cannabis, focusing on high potency infused pre-rolls and vapes [32][34] Question: Exit from the Netherlands and update on France - Management cited production cost advantages and regulatory challenges as reasons for exiting the Netherlands, while providing an update on the pilot program in France [37][39] Question: Australia's potential as a large medical market - Management highlighted the nascent nature of the Australian market and provided insights into market size projections based on prescription data [42][44] Question: German market outlook and recreational cannabis - Management expressed optimism about the medical market in Germany and the potential for legislative changes, while noting that recreational cannabis developments may take longer [46][48] Question: Improvement in gross margins - Management attributed margin improvements to higher medical cannabis sales and operational efficiencies, alongside increased yields from production [51][53]